Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | CPA1 | P15085 | 5/20 | 0.34 |
| ▸ | GSR | P00390 | 1/20 | 0.31 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22611875 | 1.00 | ALDH1A1 (0.38) | ALDH1A1TDP1LMNAL3MBTL1CPA1 | |
| SCHEMBL20088835 | 1.00 | ALDH1A1 (0.38) | ALDH1A1TDP1LMNAL3MBTL1CPA1 | |
| SCHEMBL22611876 | 1.00 | ALDH1A1 (0.38) | ALDH1A1TDP1LMNAL3MBTL1CPA1 | |
| SCHEMBL11045266 | 0.89 | ALDH1A1 (0.41) | ALDH1A1TDP1LMNACPA1TSHR | |
| SCHEMBL9809656 | 0.85 | LMNA (0.52) | ALDH1A1TDP1LMNAL3MBTL1CPA1 | |
| SCHEMBL9809638 | 0.85 | LMNA (0.52) | ALDH1A1TDP1LMNAL3MBTL1CPA1 | |
| SCHEMBL5518124 | 0.85 | LMNA (0.52) | ALDH1A1TDP1LMNAL3MBTL1CPA1 | |
| SCHEMBL9809650 | 0.85 | LMNA (0.52) | ALDH1A1TDP1LMNAL3MBTL1CPA1 | |
| SCHEMBL5521521 | 0.85 | LMNA (0.52) | ALDH1A1TDP1LMNAL3MBTL1CPA1 | |
| SCHEMBL8821198 | 0.85 | LMNA (0.52) | ALDH1A1TDP1LMNAL3MBTL1CPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11008358-B2 | Synthesis of desosamines | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2021-05-18 | — | — | US | disclosed |
| US-20200347087-A1 | SYNTHESIS OF DESOSAMINES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2020-11-05 | — | — | US | disclosed |
| US-10544182-B2 | Synthesis of desosamines | Presidents and Fellow of Harvard College (US) | 2020-01-28 | — | — | US | disclosed |
| US-20180111956-A1 | SYNTHESIS OF DESOSAMINES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2018-04-26 | — | — | US | disclosed |
| US-20180111956-A1 | SYNTHESIS OF DESOSAMINES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2018-04-26 | — | — | US | disclosed |
| EP-3277701-A1 | SYNTHESIS OF DESOSAMINES | President and Fellows of Harvard College (US) | 2018-02-07 | — | — | EP | disclosed |
| WO-2016154533-A1 | SYNTHESIS OF DESOSAMINES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-09-29 | — | — | WO | disclosed |
| WO-2016154533-A1 | SYNTHESIS OF DESOSAMINES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11008358-B2 | Synthesis of desosamines | NANS, GALE, FUT6 | ALDH1A1 1109/4885TDP1 2664/4885LMNA 706/4885 |
| US-10544182-B2 | Synthesis of desosamines | NANS, GALE, FUT6 | ALDH1A1 1109/4885TDP1 2664/4885LMNA 706/4885 |
| US-20180111956-A1 | SYNTHESIS OF DESOSAMINES | NANS, GALE, FUT6 | ALDH1A1 1109/4885TDP1 2664/4885LMNA 706/4885 |
| US-20200347087-A1 | SYNTHESIS OF DESOSAMINES | NANS, GALE, FUT6 | ALDH1A1 1109/4885TDP1 2664/4885LMNA 706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.